Videos

New 26-week COMP006 data show durable MADRS improvement after 2 COMP360 psilocybin doses in treatment-resistant depression, Dunlop explains.

Massie, Donnelly, and Mankowski discuss how transplant center choice shapes kidney transplant evaluation and access.

5 dermatology takeaways from Maui Derm NP+PA Summer 2026, covering eczematous dermatitis, rosacea, blistering disease, hair loss, and pigmentation disorders.

Sripal Bangalore, MD, discusses his recent study proposing that early intervention can lead to better cardiovascular outcomes among these patients.

In this SDPA interview, Matthew Zirwas, MD, highlights key takeaways from his session 'Clinical Pearls for Optimizing Dermatologic Care.'

Beyond hemodynamics and treatment targets, McDevitt says the most important conversations APPs have with patients are often the ones that don't appear in guidelines.

Beyond hemodynamics and treatment targets, McDevitt says the most important conversations APPs have with patients are often the ones that don't appear in guidelines.

Kimberly Blumenthal, MD, explains how to risk-stratify drug allergy labels before surgery and identify likely culprits in perioperative reactions.

Jeffrey Weitz, MD, secretary general of the ISTH, discusses the recent analysis of the AXIOMATIC-TKR trial and its implications for FXIa inhibition.

FIND-CKD demonstrated reduced eGFR decline in patients with nondiabetic CKD, providing new data for a population of >50% of CKD cases.

Matthew Zirwas, MD, speaks in this SDPA interview about evidence for atopic dermatitis being more of an environmental disease than a genetic one.

Combination therapy outperformed excimer light alone for vitiligo, according to Giovanni Leone, MD.

Chiadi Ndumele, MD, PhD, breaks down the new guidelines and how they should be implemented in this sweeping document.

4-year PIONEER data show avapritinib sustains symptom control and improves emotional well-being and social functioning in ISM, per Thanai Pongdee, MD.

Stevan Gonzalez, MD, MS, explains patient characteristics and social determinants of health associated with chronic liver disease.

As July is UV Safety Awareness Month, key tips for addressing sun damage, skin cancer signs, photoaging, and more are highlighted in this discussion.

Martin discussed where hydroquinone still fits, why oral tranexamic acid remains underused, and how he decides when to escalate to procedural therapy.

Andrew Adams, MD, PhD, discusses Bestow Phase 2 data in tegoprubart compared to tacrolimus.

Parag Joshi, MD, highlights CAC scoring’s value as a prognostic tool for lipid-lowering therapy.

Piotr Witkowski, MD, PhD, discusses the CD40L inhibitor’s efficacy in improving outcomes for patients with T1D undergoing islet transplant.

Justin Gregory, MD, MPH, and Steve Zortman, MPH, RN, discuss the critical need for early detection and intervention in this underrepresented population.

At Maui Derm NP+PA Summer 2026, Benjamin Ungar, MD, discussed early clues for scarring alopecia, pipeline JAK inhibitors, and setting patient expectations.

Earlier diagnosis is imperative for chronic liver disease; Stevan Gonzalez, MD, MS, explains how PCPs and community-based screening programs can help.

Richard Shi, MD, and Adam Tanious, MD, MBA, discuss the suboptimal number of patients at risk of long-term complications due to nonadherence.

In this SDPA interview, Murase provides tips for clinicians on conversations related to pregnancy, safety, and skin disease management.

Topical ruxolitinib shows sustained repigmentation over years, while oral JAK inhibitors move toward approval for widespread disease, George Martin, MD, says.

Nearly half of kidney transplant candidates never start evaluation with access barriers varying by patient background.

Richard Shi, MD, and Adam Tanious, MD, MBA, discuss the importance of exercise, medical interventions, and smoking cessation for PAD care.